论文部分内容阅读
目的分析瑞替普酶溶栓治疗急性心肌梗死患者的临床疗效。方法选取我院收治的100例ST段抬高性急性心肌梗死患者作为研究对象,观察组52例患者采用瑞替普酶溶栓治疗,对照组48例患者采用尿激酶进行治疗,两组患者其他治疗相同,对比分析两组临床疗效。结果治疗后,观察组总有效率优于对照组,血管再通率高于对照组,血管开通时间短于对照组患者,差异均有统计学意义(P<0.05)。结论瑞替普酶溶栓治疗急性心肌梗死具有血管开通率高、时间短、出血程度轻等优点,值得临床推荐。
Objective To analyze the clinical efficacy of reteplase thrombolysis in patients with acute myocardial infarction. Methods A total of 100 patients with ST-segment elevation acute myocardial infarction admitted to our hospital were enrolled in this study. Fifty-two patients in the observation group were treated with reteplase thrombolysis and 48 in the control group were treated with urokinase. The other two groups The same treatment, comparative analysis of two groups of clinical efficacy. Results After treatment, the total effective rate in the observation group was better than that in the control group. The rate of vascular recanalization was higher than that of the control group, and the time of vascular opening was shorter than that of the control group. The difference was statistically significant (P <0.05). Conclusion The reteplase thrombolytic therapy of acute myocardial infarction has the advantages of high rate of vascular opening, short time and mild bleeding, which is worthy of clinical recommendation.